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Objectives: To determine human papillomavirus (HPV) types in invasive cervical cancer in Portugal.
Methods: Cases diagnosed at the Instituto Português de Oncologia de Lisboa de Francisco Gentil
from the year 1928 to 2005 were selected for HPV DNA detection and genotyping using SPF10/DEIA/
LiPA25 system.
Results: Of the 1214 samples that were considered appropriate for HPV detection, 714 (58.8%; 95% CI:
56.0–61.6%) were positive for HPV DNA. This detection rate varied being lower in the ﬁrst 3 decades
(31.3%; 50.1%; 46.5%) and higher in the last decades (77.4–95.1%). This difference was due probably to the
ﬁxative used in the ﬁrst three decades. The ﬁve most common types identiﬁed among HPV positive cases
were HPV16 (58.2%), HPV18 (9.2%), HPV33 (6.2%), HPV45 (4.7%) and HPV31 (4.4%). Multiple infections
were detected in 2.8% of the cases. HPV16 and 18 accounted for 67.4% of infections. There were no
statistically signiﬁcant changes of these types over the studied period. An increase at patient's age at
diagnosis was observed in the last decades (po0.001).
Conclusion: HPV16 and 18 accounts for almost 70% of cervical cancers in all 9 decades studied and
support data that effective vaccination against these 2 types will reduce the cervical burden in
Portuguese women.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human Papillomavirus (HPV) infection is causally linked to
invasive cervical cancer (ICC) [1]. In Portugal the incidence of ICC is
high (age-standardized rate of 10.8 cases per 100,000 women),
and mortality is estimated to be 4.9 deaths per 100,000 women
[2]. Accordingly with the results of the CLEOPATRE Portuguese
study, overall HPV prevalence was estimated to be 19.4%, in the
general female population [3]. This was the ﬁrst large study on
HPV infection in the general population and the extrapolated
prevalence for HPV infection was higher than the one obtained in
other neighbor countries such as Spain, with HPV prevalence in
general female of a 14.3% [4]. The higher incidence and mortality
of cervical carcinoma in Portugal could be related to a higher
prevalence of HPV infection and most probably related with then open access article under the C
tológica, Instituto Português de On
ms.unl.pt (A. Félix), lalemany@ico
.cat (F.X. Bosch).absence of a National Cervical Cancer Screening Programme,
although planed, is still not implemented. In Portugal, in 2008,
quadrivalent HPV vaccination was included in the National
Immunization Plan for girls aged 13, having an overall coverage
rate of 88 and 93% [5].
There is scarce data regarding HPV distribution in ICC in the
Portuguese population [6,7]. Large international series demon-
strate that, although a small number of different types are more
prevalent than others, there are some geographical differences
regarding HPV type distribution [8]. Our aim was to describe the
HPV genotype distribution in ICC in Portugal, to analyze differ-
ences in along nine decades (from 1928 to 2005). This study is part
of a larger study, RIS HPV TT study [9], whose objective was to
describe the HPV genotype distribution in invasive cervical cancer
worldwide.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1309 cases with the diagnosis of ICC and treated in the Instituto
Português de Oncologia de Lisboa de Francisco Gentil (IPOLFG)
were identiﬁed. Between 1928 until 1939, all available cases were
retrieved, and from the year 1940 to the year 2005, consecutive
cases diagnosed during the months of March and April on even-
years of the decade were selected. All tumor samples were ﬁxed
and included in parafﬁn blocks. The ﬁxative ﬂuid varied along the
decades. In the period from 1928 to 1944, almost all cases were
ﬁxed in Bouin. After that year of 1944, all cases were ﬁxed in
formalin, being buffered formalin used beyond 2000. After histo-
logical veriﬁcation at Catalan Institut of Oncology-ICO (Spain), a
total of 1214 cases were ﬁnally selected for HPV detection and
genotyping.
All clinical charts were reviewed to conﬁrm tumor site and
patient age at the time of diagnosis.Table 1
Clinical data by decade (number of cases, age and histological diagnosis).
Decades No. of cases (%) Mean age (range) Histology
[age registry missing] SCC/ non SCC
1928–29 112 48 (24–74) 106/6
(9.2%) [2]
1930–39 684 50 (25–85) 623/61
(56.3%) [34]
1940–49 86 50 (29–76) 83/3
(7.1%) [4]
1950–59 88 50 (28–77) 83 /5
(7.2%) [6]
1960–69 66 57 (31–85) 65/1
(5.4%) [7]
1970–79 50 57 (20–85) 47/3
(4.1%) [0]
1980–89 56 56 (29–84) 52/4
(4.6%) [1]
1990–99 31 59 (31–94) 26/5
(2.6%) [0]
2000–05 41 57 (32–88) 41/0
(3.4%) [0]
Total 1214 53 (24–94) 1126/88
(100%) [54]
Legends: “SCC” – Squamous Cell Carcinoma; “non SCC” – non Squamous Cell
Carcinoma.2.1. Pathology and HPV detection protocol
Tumor samples were re-embedded in parafﬁn blocks (when it
was needed) and tested at Catalan Institute of Oncology-ICO
(Spain) for HPV DNA. All the methodology has been previously
described in de Sanjosé et al. [9]. Brieﬂy, four sections were done
(ﬁrst and last were stained with haematoxylin and eosin (H&E)
and used to conﬁrm the diagnosis and to evaluate the adequacy of
the tissue to retrieve DNA and the two in-between collected to an
eppendorf tube for HPV detection with the adequate precautions
of contamination. As control, blocks from all years corresponding
to those of tumor samples from other locations not HPV related
(appendix, breast, and thyroid) were used.
Proteinase K (Sigma) digestion for 16 h at 56 °C temperature
was used to obtain a tissue lysate containing DNA from the par-
afﬁn inner 5 mm sections. SPF-10 PCR was performed using 10 ml of
a 1:10 dilution with water of the tissue digest in a ﬁnal reaction
volume of 50 ml. The ampliﬁed PCR products were tested using a
hybridization probe with a cocktail of conservative probes recog-
nizing at least 54 mucosal HPV types in a microtitre plate format
for the detection of HPV DNA. Optical densities (OD450) were read
on a microtitre plate reader. HPV DNA positive samples were
subsequently analyzed by the reverse hybridization line probe
assay (LiPA25) (version 1; produced at Labo Biomedical Products
Rijswijk, The Netherlands), a technique that detects 25 high risk
and low risk HPV types (6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43,
44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68/73, 70, 74). The sequence
variation within the SPF-10 primers allows the recognition of the
different HPV types, except for the types 68 and 73 as theirs
interprimer regions are identical and cannot be distinguished on
this test. The positive hybridization on the strips is visualized as a
purple band by means of a precipitating color substrate on the
probe site. Specimens that were HPV DNA positive by DEIA (DNA-
Elisa) but did not hybridize with any of the 28 probes in the LiPA25
were further analyzed by sequencing. Further, specimens that
were HPV 68 or 73 or HPV 39 or HPV 68 or HPV 73 were also
sequenced to discriminate the speciﬁc type as described in de
Sanjosé et al. [9]. HPV detection was analyzed by histological
classiﬁcation (squamous cell carcinoma, adenocarcinoma or
other), patient age, and time at diagnosis. Multiple infections were
counted as weighted proportional attribution model as described
in de Sanjosé et al. [9]. Linear trend test was used to evaluate
changes over time. Statistical signiﬁcance cut point was set at
2-sided 0.05.3. Results
A total of 1309 cases with the diagnosis of ICC were retrieved
and 1214 cases were ﬁnally selected for HPV detection and geno-
typing. 95 cases were discarded for further analysis due to high
proportion of necrosis, non-invasive tumor conﬁrmed on the H&E
slides and poorly preserved parafﬁn block. Table 1 shows the
distribution of ICC cases by time at diagnosis and age and histo-
logical characteristics of the cases included in the HPV analysis.
The distribution of tumor samples by decades showed that
approximately half of the cases (56.3%) were from the 1930-39
decade and the remaining decades had similar representation
showing proportions from 3% to 9%. Patient's mean age at diag-
nosis was 53 years old and ranged between 20 and 94 years. In 54
cases, age was unknown (not registered in the clinical ﬁles). Mean
age of patients at the date of diagnosis showed signiﬁcant differ-
ences between decades. Mean age between 1920 and 1959
was statistically lower than in more recent decades (7 years;
p-valueo0.001).
Regarding the morphological features, squamous cell carci-
noma (SCC) was the most common histological type correspond-
ing to 1126 cases (92.8%), followed by adenocarcinoma (63 cases;
5.2%), adenosquamous carcinoma (7 cases; 0.6%) and the remain-
ing 18 (1.5%) were tumors classiﬁed as other types (10 undiffer-
entiated and 8 neuroendocrine carcinomas). SCC was the most
common histological type over all decades (more than 90%).
The presence of HPV DNA in cervical carcinomas was detected
in 714 cases (overall detection rate was 58.8%; 95% conﬁdence
interval-CI: 56.0–61.6%). The higher detection rate was obtained in
last decade (95.4%) and lower rate from older cases of 1920–1030
(35.3%). A low detection rate of HPV DNA was also obtained in
cases diagnosed between 1930 and 1949 (around 50%). In the
subsequent decades, HPV DNA detection was higher ranging from
77.4% to 95.1%.
Single, multiple and unknown types were identiﬁed in a 95.7%,
2.8% and 1.5%, respectively. Table 2 shows the detection of HPV by
decade, HPV detection increased with the year of diagnosis
(p trend test o0.05). Table 3 shows HPV type distribution by
decades, among HPV positive cases. The most common DNA
viruses were HPV16 (58.2%) and 18 (9.2%) with an overall pre-
valence of 67.4%, followed by HPV33 (6.2%), HPV45 (4.7%), HPV31
Table 2
HPV detection by decade.
1928–1929 1930–1939 1940–1949 1950– 1959 1960– 1969 1970–1979 1980– 1989 1990– 1999 2000–2005 Total
No. of cases 112 684 86 88 66 50 56 31 41 1214
HPV DNA positive (N;%)n 35 (31.3%) 343 (50.1%) 40 (46.5%) 82 (93.2%) 58 (87.9%) 46 (92.0%) 47 (83.9%) 24 (77.4%) 39 (95.1%) 714 (58.8%)
HPV DNA positive (95% CI) 22.8–40.7 46.3–54.0 35.7–57.6 85.7–97.5 77.5–94.6 80.8–97.8 71.7–92.4 58.9–90.4 83.5–99.4 56.0–61.6
No of Single HPV 34 325 40 80 55 44 46 22 37 683
No Multiple HPV 1 8 0 2 3 2 1 1 2 20
No of HPV Undetermined 0 10 0 0 0 0 0 1 0 11
Legend: "*": N - number of cases; % percent; "95%CI": 95% conﬁdence interval.
Table 3
Distribution of HPV DNA types by decades.
HPV typen 1928–29 1930–39 1940–49 1950–59 1960–69 1970–79 1980–89 1990–99 2000–05 Total
N % N % N % N % N % N % N % N % N % N %
11 0 0.0 1 0.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1
16 24 68.6 188 54.8 24 60.0 48 58.5 36 61.8 30 65.2 26 55.0 16 66.7 24 61.5 415 58.2
18 2 5.7 39 11.4 8 20.0 4 4.9 4 6.7 3 6.5 4 8.8 0 0.0 1 2.6 66 9.2
30 0 0.0 2 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.6 3 0.4
31 1 2.9 15 4.4 2 5.0 3 4.0 3 5.2 2 4.3 1 2.1 2 8.3 2 5.1 31 4.4
33 0 0.0 19 5.5 1 2.5 9 10.6 7 12.1 3 6.5 3 6.4 2 8.3 1 2.6 45 6.2
35 2 5.7 4 1.3 2 5.0 2 2.4 0 0.0 1 2.2 2 4.3 2 8.3 4 10.3 19 2.6
39 0 0.0 7 2.0 0 0.0 2 2.4 1 2.2 0 0.0 1 2.1 0 0.0 0 0.0 11 1.6
39n 0 0.0 2 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.3
42 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.6 1 0.1
45 3 8.6 19 5.5 0 0.0 5 6.1 3 5.2 0 0.0 2 4.3 0 0.0 2 5.1 34 4.7
51 0 0.0 4 1.2 1 2.5 2 2.4 0 0.0 1 2.2 0 0.0 1 4.2 0 0.0 9 1.3
52 0 0.0 9 2.5 0 0.0 4 4.9 0 0.0 2 4.3 1 2.1 0 0.0 2 5.1 17 2.4
53 0 0.0 1 0.3 0 0.0 0 0.0 1 1.7 0 0.0 0 0.0 0 0.0 0 0.0 2 0.3
56 0 0.0 4 1.2 2 5.0 0 0.0 0 0.0 1 2.2 1 2.1 0 0.0 0 0.0 8 1.1
58 2 5.7 5 1.5 0 0.0 2 2.4 1 1.7 1 2.2 0 0.0 0 0.0 0 0.0 11 1.5
59 0 0.0 5 1.5 0 0.0 0 0.0 0 0.0 1 2.2 4 8.5 0 0.0 0 0.0 10 1.4
66 0 0.0 1 0.3 0 0.0 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 2 0.3
67 0 0.0 1 0.3 0 0.0 0 0.0 1 1.7 0 0.0 0 0.0 0 0.0 0 0.0 2 0.3
68 0 0.0 1 0.3 0 0.0 1 1.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.3
68n 1 2.9 3 0.9 0 0.0 0 0.0 0 0.0 0 0.0 1 2.1 0 0.0 0 0.0 5 0.8
69 0 0.0 1 0.3 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1
70 0 0.0 2 0.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 2 0.3
73 0 0.0 0 0.0 0 0.0 0 0.0 1 1.7 1 2.2 0 0.0 0 0.0 0 0.0 2 0.3
91 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 2.6 1 0.1
Undetermined 0 0.0 10 2.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 4.2 0 0.0 11 1.5
Legend: “n”: single infections and multiple infections counted following a weighting algorithm, “%” are estimated among HPV DNA positive cases; 39n – 39 or 68 or 73 HPV
types; 68n – 68 or 73 HPV types; “Undetermined” – unknown HPV type or types.
Table 4
Distribution of the more common HPV types by histology.
SCC ADC ADSCC OTHER Total
N % N % N % N % N %
Cases analyzedn 1126 92.8 63 5.2 7 0.6 18 1.5 1214 100
HPV DNA positivenn 681 60.5 20 31.7 2 28.6 11 61.1 714 58.8
HPV typennn
16 395 58.1 11 55.0 1 50.0 8 72.7 415 58.2
18 56 8.2 7 35.0 1 50.0 2 18.2 66 9.2
33 44 6.5 0 0.0 0 0.0 0 0.0 45 6.2
45 32 4.7 2 10.0 0 0.0 0 0.0 34 4.7
31 31 4.6 0 0.0 0 0.0 0 0.0 31 4.4
35 18 2.6 0 0.0 0 0.0 1 9.1 19 2.6
52 17 2.5 0 0.0 0 0.0 0 0.0 17 2.4
39 11 1.6 0 0.0 0 0.0 0 0.0 11 1.6
58 11 1.6 0 0.0 0 0.0 0 0.0 11 1.5
Undetermined 11 1.6 0 0.0 0 0.0 0 0.0 11 1.5
Legend: “SCC” – Squamous Cell Carcinoma; “ADC” – Adenocarcinoma; “ADSCC” –
Adenosquamous Cell Carcinoma; “OTHER” – Other histological diagnosis; “Unde-
termined” – unknown HPV type or types.
n Percent among all cases.
nn Percent among HPV analyzed cases by histological diagnosis.
nnn Percent among HPV DNA positive cases by histological diagnosis.
A. Félix et al. / Papillomavirus Research 2 (2016) 41–45 43(4.4%), HPV35 (2.6%), HPV52 (2.4%), and HPV39 (1.6%). In 10 cases a
low risk HPV type was detected, but only in 4 cases there was a
low risk HPV type detected as single infection (one HPV42, one
HPV11 and two HPV70), and in the rest, these types were found as
part of co-infection with other types, most of them high risk types
(HPV6 and HPV16 in two cases; and HPV74 and HPV16 in four
other cases). Regarding time at diagnosis, no trends neither for
HPV16 nor HPV18 over time were observed. The average age at
diagnosis showed differences by HPV type. Mean age of patients
with HPV18 and HPV45, as single infection was 49.1 and 47.1 years
old, respectively. In contrast, mean age of patients infected by
HPV16, HPV33 and HPV31 was 51.2, 57.0 and 55.6 years old,
respectively. Patients, in this last group, were signiﬁcantly older
than patients harboring HPV types 18 and 45.
Table 4 shows the HPV type distribution by histological type. In
adenocarcinoma cases, the second most common histological type
(5.2%) after squamous cell carcinoma, HPV detection rate (31.7%)
was very low compared to the previous type (60.5%). The most
frequently HPV types detected in the 20 HPV positive adenocarci-
nomas, were HPV16 (55.0%), HPV18 (35.0%), and HPV45 (10.0%). The
ﬁve most common types identiﬁed in SCC were, HPV16 (58.1%),
HPV18 (8.2%), HPV33 (6.5%), HPV45 (4.7%), and HPV31 (4.6%).
A. Félix et al. / Papillomavirus Research 2 (2016) 41–45444. Discussion
This is a historical retrospective analysis along nine decades of
ICC diagnosed and treated in just one cancer institution covering
the southern part of Portugal. This data was not disturbed by
external factors, such as organized national cervical cancer
screening, as it was not implemented in southern part of Portugal.
In this cohort, age at diagnosis of ICC was 53.3 years old. This
value is within the range of values in other countries [10]. In the
evaluation of mean age and age range along the 90 years of this
study, we found a signiﬁcant difference between the ﬁrst and last
decades of the 20th century. Patients diagnosed between 1928 and
1959 had a lower mean age at diagnosis than patients diagnosed in
more recent decades. In the ﬁrst 40 years of this study, patient's
mean age at diagnosis was 50.4 years old (SD 10.3) and in the
subsequent years the mean age was 7 years signiﬁcantly higher
(57.7 years old with SD 14.1; p-valueo0.001). This increased age
at diagnosis by decades was also observed in Sweden, where a
small increase (4.3 years) on incidence age at diagnosis was
reported [11], although in their study, no statistically difference
was reported. Many factors can be held responsible for this inci-
dence change, such as better health care system and changes in
known risk factors. During these nine decades modiﬁcations have
occurred regarding protective effects and risk factors. For instance,
a better health care system and an improved education of the
population were developed; and at same time risks factors such as
use of contraceptive pills and cigarette smoking were introduced
or increased. Organized screening cannot be held as a contribute
factor to this change of the delayed age of presentation in these
last decades, as a no organized cervical screening practices existed
in this region of Portugal.
Clinical data from the 1214 cases showed a wide variation of
tumor staging at the time of diagnosis, treatment and patient
survival (data not showed) reﬂecting the very large span of
the study.
In this study, we obtained an overall detection rate of HPV DNA
in ICC of 58.8% (95% CI: 56.0-61.6%). This rate was very low com-
pared to series reporting a prevalence of HPV DNA detection of
almost a 100% [1]. The low overall rate of this series is due to the
very low HPV DNA detection in the ﬁrst two decades. In 112
samples from 1928 to 1929, HPV DNA was found in 35 (31.3%),
being slightly more elevated (around 50%) between 1930 and
1949. HPV DNA detection range was from 77.4% to 95.1% in the
subsequent decades. The explanation of this low rate of HPV DNA
detection was due to the ﬁxative used for tissue preservation. Till
1944, in our department, Bouin was used as the main ﬁxative for
specimen preservation. This ﬁxative, although known by its ability
to preserve nuclear details, was also associated with poorly DNA
and RNA preservation for molecular studies [12,13] and a special
retrieval protocol is needed to obtain better results but it was not
used in this study. In the following decades specimens were ﬁxed
in formalin resulting in higher rates of HPV DNA detection. A
special recovery protocol should have been applied to cases from
1944 and before in order to verify if the prevalence rate of HPV
DNA obtained with the used protocol in this study is real or
underestimated.
Regarding HPV DNA types, the large majority of cases had just
one genotype of HPV DNA. Only in 20 cases (2.8%) multiple HPV
types were identiﬁed. In 11 cases (1.5%), although HPV DNA was
identiﬁed, the types were not recognized by the SPF10/DEIA/LiPA
kit and subsequent sequencing analysis. In our series, we were
able to establish the proﬁle of HPV genotype in invasive carcino-
mas in Portugal. The most common HPV types in cervical carci-
noma of Portuguese women were HPV16, 18, 33, 45, 31, 35, 52, 39
and 58 by order of frequency. Invasive cervical tumors were
associated with the presence of the most common high-risk HPVtypes, with a similar but not identical distribution to the rest of the
European countries [9]. The third more common type in our series
was HPV33 and not HPV45. This last type ranked in fourth place.
Data on the distribution of HPV types in ICC in Portugal is very
scarce, but the results of our series were slightly different from
previous results reported [5]. Medeiros et al. [5] found HPV16 and
HPV18 in 80% and 15%, respectively in their series of 60 cases of
ICC. Both results are higher than the obtained in our cohort and
differences might be explained by the larger sample of our study
or differences in methodological criteria.
We did not observed statistically signiﬁcant variations regard-
ing HPV DNA types 16–18 in cancer over the decades, being HPV16
the most frequent type, in all decades (58.2%), of all viruses
detected followed by HPV18 (9.2%).
We, as other did previously, also observed a lower age at
diagnosis of cervical cancer attributable to HPV16, HPV18 and
HPV45 [14–16]. This ﬁnding might be important regarding the
beginning of screening of HPV vaccinated cohorts, as HPV45 type
is not included in quadrivalent vaccine.
The overall detection of HPV DNA was different accordingly to
the histological type. In squamous cell carcinoma cases HPV DNA
detection was almost the double than in adenocarcinoma type.
Several explanations can be advance to explain our results such as
non-HPV related cervical adenocarcinomas, contamination of the
series with endometrial primary adenocarcinomas, worse DNA
retrieval in adenocarcinoma cases due to ﬁxation or other factors.
A higher prevalence rate of HPV DNA in adenocarcinomas diag-
nosed at IPOLFG, using a similar HPV detection protocol, from the
2000-10 decade in a small series of cervical adenocarcinomas was
obtained. In that series, 89% of cases (33/37) were HPV DNA
positive [17]. The explanation of this ﬁnding maybe is related with
the small number of adenocarcinomas cases studied in this series
after 1980 (6 out 63 cases).
In our series HPV33, the third more prevalent genotype in
squamous cell carcinomas (6.2%) was not found in any other his-
tological types. This association between HPV types and histology
has been suggested in many reports, as for example, in adeno-
carcinomas, HPV18 and HPV45 are more common than in squa-
mous cell carcinoma. This last association is also found in this
study as well as the previous one [17]. Given the excellent vacci-
nation coverage rate achieved in Portugal, a special program in a
near future can be organized in order to study the presence and
the HPV types in vaccinated women population, as cross protec-
tion is low with quadrivalent HPV vaccine that is currently
implemented in Portugal.
In conclusion, in this historical retrospective analysis of inva-
sive carcinoma of the cervix, diagnosed and treated in one cancer
institution in Portugal, we characterized HPV genotype proﬁle of
invasive carcinomas of the cervix along the XX century. As in other
countries HPV16 and HPV18 were the most common types
representing 67.4% of all cases. We were able to verify that there
were no changes of the most prevalent HPV types throughout the
nine decades that comprised this study. We also found that in the
Portuguese population the most prevalent HPV types in cervical
carcinoma are not the same types responsible for HPV infection.
This information can be important in the evaluation of the results
of the Immunization Plan and in the development of second-
generation HPV vaccines. Moreover, as in other countries, the
implementation of the 9vHPV vaccine will allow to cover around
85% of HPV types in invasive cervical carcinomas in Portugal.Conﬂict of interest statement
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